Contact Us
As renowned leaders in clinical and research accomplishments in type 1 and type 2 diabetes, the pediatric endocrine team is the region's leader in diagnosing and treating children with diabetes. Our physicians, nurse practitioners, dietitians, psychologist and social worker in the type 1 diabetes program have set a standard of care that is unmatched elsewhere in the country. Our multidisciplinary team of clinicians who care for children and adolescents with type 2 diabetes and other complications of childhood obesity, provide a range of services that includes one-on-one lifestyle counseling and a novel life-style intervention program.
Patients diagnosed with type 1 or type 2 diabetes are routinely admitted to Yale New Haven Children's Hospital for initial evaluation and treatment. During these short, 1- to 2-day hospitalizations, families are assisted in coping with the psychological stress of the diagnosis, as well as learning basic diabetes management skills.
The pediatric endocrine team participates in research that focus on better care of diabetes in children and adolescents. Additional research projects are aimed at understanding the causes of autoimmune (juvenile) diabetes and the development of interventions to prevent diabetes. By employing state-of-the-art diabetes technology and a multidisciplinary approach to diabetes management, the pediatric diabetes program at Yale New Haven Children's Hospital has set a national standard for the percentage of patients who have achieved target blood glucose and hemoglobin A1c levels, resulting in the prevention of early diabetic eye disease in our patients.
Together with our physician-researchers at Yale School of Medicine, we pioneered an advanced treatment for children and adults at risk for developing type 1 diabetes (T1D). TZIELD® (teplizumab-mzwv) is a treatment to help delay the onset of Stage 3 type 1 diabetes, which occurs most commonly in childhood, but can also be developed in adulthood. This treatment involves 14 consecutive days of intravenous (IV) therapy and provides children and families more time to live without the disease.
The treatment is approved for those at high risk for T1D and who have abnormal blood sugar levels. To meet the criteria for “high risk,” a person must have a family history of T1D and a screening test that confirms the presence of at least two autoantibodies that indicate that the body is already attacking the insulin-producing beta cells in the pancreas. Screening for T1D autoantibodies is important for early detection and treatment of the condition. Comprehensive tests and screenings are performed to determine eligibility for the treatment.
The delay in the onset of stage 3 T1D is extremely significant, especially for a child and their family, providing more time to prepare for the challenges that can be associated with stage 3 disease.
The Weight Solutions Program incorporates a varied approach to addressing childhood obesity through prevention, education and understanding its causes. A teen weight management program that includes counseling, healthy lifestyle recommendations, nutrition and cognitive therapy is led by experts in their respective fields.
Yale New Haven Health is proud to be affiliated with the prestigious Yale University and its highly ranked Yale School of Medicine.
